Highlights
The global Leiomyosarcoma Drug market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Leiomyosarcoma Drug is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Leiomyosarcoma Drug is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Leiomyosarcoma Drug include Advenchen Laboratories, LLC, BeiGene, Ltd., Cell Medica Limited, Karyopharm Therapeutics, Inc., Merck & Co., Inc., Mirati Therapeutics Inc., Novartis AG and Vicore Pharma AB, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Leiomyosarcoma Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Leiomyosarcoma Drug.
The Leiomyosarcoma Drug market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Leiomyosarcoma Drug market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Leiomyosarcoma Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Advenchen Laboratories, LLC
BeiGene, Ltd.
Cell Medica Limited
Karyopharm Therapeutics, Inc.
Merck & Co., Inc.
Mirati Therapeutics Inc.
Novartis AG
Vicore Pharma AB
Segment by Type
AL-3818
BGB-290
C-21
Others
Segment by Application
Clinic
Hospital
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Leiomyosarcoma Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Leiomyosarcoma Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Leiomyosarcoma Drug Market Overview
1.1 Product Overview and Scope of Leiomyosarcoma Drug
1.2 Leiomyosarcoma Drug Segment by Type
1.2.1 Global Leiomyosarcoma Drug Market Value Comparison by Type (2023-2029)
1.2.2 AL-3818
1.2.3 BGB-290
1.2.4 C-21
1.2.5 Others
1.3 Leiomyosarcoma Drug Segment by Application
1.3.1 Global Leiomyosarcoma Drug Market Value by Application: (2023-2029)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Global Leiomyosarcoma Drug Market Size Estimates and Forecasts
1.4.1 Global Leiomyosarcoma Drug Revenue 2018-2029
1.4.2 Global Leiomyosarcoma Drug Sales 2018-2029
1.4.3 Global Leiomyosarcoma Drug Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Leiomyosarcoma Drug Market Competition by Manufacturers
2.1 Global Leiomyosarcoma Drug Sales Market Share by Manufacturers (2018-2023)
2.2 Global Leiomyosarcoma Drug Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Leiomyosarcoma Drug Average Price by Manufacturers (2018-2023)
2.4 Global Leiomyosarcoma Drug Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Leiomyosarcoma Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Leiomyosarcoma Drug, Product Type & Application
2.7 Leiomyosarcoma Drug Market Competitive Situation and Trends
2.7.1 Leiomyosarcoma Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Leiomyosarcoma Drug Players Market Share by Revenue
2.7.3 Global Leiomyosarcoma Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Leiomyosarcoma Drug Retrospective Market Scenario by Region
3.1 Global Leiomyosarcoma Drug Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Leiomyosarcoma Drug Global Leiomyosarcoma Drug Sales by Region: 2018-2029
3.2.1 Global Leiomyosarcoma Drug Sales by Region: 2018-2023
3.2.2 Global Leiomyosarcoma Drug Sales by Region: 2024-2029
3.3 Global Leiomyosarcoma Drug Global Leiomyosarcoma Drug Revenue by Region: 2018-2029
3.3.1 Global Leiomyosarcoma Drug Revenue by Region: 2018-2023
3.3.2 Global Leiomyosarcoma Drug Revenue by Region: 2024-2029
3.4 North America Leiomyosarcoma Drug Market Facts & Figures by Country
3.4.1 North America Leiomyosarcoma Drug Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Leiomyosarcoma Drug Sales by Country (2018-2029)
3.4.3 North America Leiomyosarcoma Drug Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Leiomyosarcoma Drug Market Facts & Figures by Country
3.5.1 Europe Leiomyosarcoma Drug Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Leiomyosarcoma Drug Sales by Country (2018-2029)
3.5.3 Europe Leiomyosarcoma Drug Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Leiomyosarcoma Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Leiomyosarcoma Drug Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Leiomyosarcoma Drug Sales by Country (2018-2029)
3.6.3 Asia Pacific Leiomyosarcoma Drug Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Leiomyosarcoma Drug Market Facts & Figures by Country
3.7.1 Latin America Leiomyosarcoma Drug Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Leiomyosarcoma Drug Sales by Country (2018-2029)
3.7.3 Latin America Leiomyosarcoma Drug Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Leiomyosarcoma Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Leiomyosarcoma Drug Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Leiomyosarcoma Drug Sales by Country (2018-2029)
3.8.3 Middle East and Africa Leiomyosarcoma Drug Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Leiomyosarcoma Drug Sales by Type (2018-2029)
4.1.1 Global Leiomyosarcoma Drug Sales by Type (2018-2023)
4.1.2 Global Leiomyosarcoma Drug Sales by Type (2024-2029)
4.1.3 Global Leiomyosarcoma Drug Sales Market Share by Type (2018-2029)
4.2 Global Leiomyosarcoma Drug Revenue by Type (2018-2029)
4.2.1 Global Leiomyosarcoma Drug Revenue by Type (2018-2023)
4.2.2 Global Leiomyosarcoma Drug Revenue by Type (2024-2029)
4.2.3 Global Leiomyosarcoma Drug Revenue Market Share by Type (2018-2029)
4.3 Global Leiomyosarcoma Drug Price by Type (2018-2029)
5 Segment by Application
5.1 Global Leiomyosarcoma Drug Sales by Application (2018-2029)
5.1.1 Global Leiomyosarcoma Drug Sales by Application (2018-2023)
5.1.2 Global Leiomyosarcoma Drug Sales by Application (2024-2029)
5.1.3 Global Leiomyosarcoma Drug Sales Market Share by Application (2018-2029)
5.2 Global Leiomyosarcoma Drug Revenue by Application (2018-2029)
5.2.1 Global Leiomyosarcoma Drug Revenue by Application (2018-2023)
5.2.2 Global Leiomyosarcoma Drug Revenue by Application (2024-2029)
5.2.3 Global Leiomyosarcoma Drug Revenue Market Share by Application (2018-2029)
5.3 Global Leiomyosarcoma Drug Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Advenchen Laboratories, LLC
6.1.1 Advenchen Laboratories, LLC Corporation Information
6.1.2 Advenchen Laboratories, LLC Description and Business Overview
6.1.3 Advenchen Laboratories, LLC Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Advenchen Laboratories, LLC Leiomyosarcoma Drug Product Portfolio
6.1.5 Advenchen Laboratories, LLC Recent Developments/Updates
6.2 BeiGene, Ltd.
6.2.1 BeiGene, Ltd. Corporation Information
6.2.2 BeiGene, Ltd. Description and Business Overview
6.2.3 BeiGene, Ltd. Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2018-2023)
6.2.4 BeiGene, Ltd. Leiomyosarcoma Drug Product Portfolio
6.2.5 BeiGene, Ltd. Recent Developments/Updates
6.3 Cell Medica Limited
6.3.1 Cell Medica Limited Corporation Information
6.3.2 Cell Medica Limited Description and Business Overview
6.3.3 Cell Medica Limited Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Cell Medica Limited Leiomyosarcoma Drug Product Portfolio
6.3.5 Cell Medica Limited Recent Developments/Updates
6.4 Karyopharm Therapeutics, Inc.
6.4.1 Karyopharm Therapeutics, Inc. Corporation Information
6.4.2 Karyopharm Therapeutics, Inc. Description and Business Overview
6.4.3 Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Karyopharm Therapeutics, Inc. Leiomyosarcoma Drug Product Portfolio
6.4.5 Karyopharm Therapeutics, Inc. Recent Developments/Updates
6.5 Merck & Co., Inc.
6.5.1 Merck & Co., Inc. Corporation Information
6.5.2 Merck & Co., Inc. Description and Business Overview
6.5.3 Merck & Co., Inc. Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Merck & Co., Inc. Leiomyosarcoma Drug Product Portfolio
6.5.5 Merck & Co., Inc. Recent Developments/Updates
6.6 Mirati Therapeutics Inc.
6.6.1 Mirati Therapeutics Inc. Corporation Information
6.6.2 Mirati Therapeutics Inc. Description and Business Overview
6.6.3 Mirati Therapeutics Inc. Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Mirati Therapeutics Inc. Leiomyosarcoma Drug Product Portfolio
6.6.5 Mirati Therapeutics Inc. Recent Developments/Updates
6.7 Novartis AG
6.6.1 Novartis AG Corporation Information
6.6.2 Novartis AG Description and Business Overview
6.6.3 Novartis AG Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Novartis AG Leiomyosarcoma Drug Product Portfolio
6.7.5 Novartis AG Recent Developments/Updates
6.8 Vicore Pharma AB
6.8.1 Vicore Pharma AB Corporation Information
6.8.2 Vicore Pharma AB Description and Business Overview
6.8.3 Vicore Pharma AB Leiomyosarcoma Drug Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Vicore Pharma AB Leiomyosarcoma Drug Product Portfolio
6.8.5 Vicore Pharma AB Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Leiomyosarcoma Drug Industry Chain Analysis
7.2 Leiomyosarcoma Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Leiomyosarcoma Drug Production Mode & Process
7.4 Leiomyosarcoma Drug Sales and Marketing
7.4.1 Leiomyosarcoma Drug Sales Channels
7.4.2 Leiomyosarcoma Drug Distributors
7.5 Leiomyosarcoma Drug Customers
8 Leiomyosarcoma Drug Market Dynamics
8.1 Leiomyosarcoma Drug Industry Trends
8.2 Leiomyosarcoma Drug Market Drivers
8.3 Leiomyosarcoma Drug Market Challenges
8.4 Leiomyosarcoma Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Advenchen Laboratories, LLC
BeiGene, Ltd.
Cell Medica Limited
Karyopharm Therapeutics, Inc.
Merck & Co., Inc.
Mirati Therapeutics Inc.
Novartis AG
Vicore Pharma AB
*If Applicable.